A Phase 3 interventional study of Tadalafil and Placebo in Benign Prostatic Hyperplasia, sponsored by Eli Lilly and Company. Completed at 5 sites in 3 countries. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2013-05-20.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 18th largest by enrollment, is one of 3 that started in 2010, is one of 10 in phase 3, and was the 12th registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
Assiut University
Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 45 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 11 · Phase 4 6
First in 2004; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 97 is close to the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 258 across the 26 interventional studies. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 26 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
17 studies in Prostatic Hyperplasia by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 17 finished, 16 (94%) have results posted.
Among the 17 studies in Prostatic Hyperplasia by Eli Lilly and Company, this one is the 16th largest by enrollment, is one of 4 that started in 2010, is one of 9 in phase 3, and was the 13th registered.
Eli Lilly and Company’s Prostatic Hyperplasia studies by the year they started, since 2004.
1 of the studies testing tadalafil in Prostatic Hyperplasia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07654413Beni-Suef UniversityTamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 17 in Prostatic Hyperplasia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to evaluate the effect of tadalafil 5 milligrams (mg) daily for 8 weeks compared to placebo on prostatic blood perfusion in men with signs and symptoms of Benign Prostatic Hyperplasia (BPH), measured by resistive index (RI) in the prostate transition zone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tadalafil
Drug: Placebo
Administered orally, once daily for 8 weeks
Also known as: Cialis, LY450190
Administered orally, once daily for 8 weeks
Change From Baseline to 8-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone
Arterial RI was a measure of vascular resistance using Doppler ultrasound. RI was the ratio of (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and increased as resistance to blood flow increased. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix.
Time frame: Baseline, Week 8
Change From Baseline to 4-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone
Arterial RI was a measure of vascular resistance using Doppler ultrasound. RI was the ratio of (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and increased as resistance to flow increased. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix.
Time frame: Baseline, Week 4
Change From Baseline to 4 and 8 Weeks in Arterial Resistive Index (RI) in the Prostate Peripheral Zone and Bladder Neck
Arterial RI was a measure of vascular resistance using Doppler ultrasound. RI was the ratio of (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and increased as resistance to flow increased. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix.
Time frame: Baseline, Week 4 and Week 8
Change From Baseline to 4 and 8 Weeks in Color Pixel Intensity (CPI) in the Prostate Transition Zone, Peripheral Zone, and Bladder Neck
CPI quantified blood flow in a pre-specified region of interest by using color Doppler imaging. CPI was the mean color pixel intensity in the region of interest and scores could range from 0 to 160. An increase in CPI reflected an increase in blood flow. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix.
Time frame: Baseline, Week 4 and Week 8
| Milestone | Placebo | Tadalafil |
|---|---|---|
| Started | 50 | 47 |
| Received at least 1 dose of study drug | 50 | 47 |
| Completed | 45 | 39 |
| Not completed | 5 | 8 |
| Withdrew: Adverse event | 2 | 4 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 3 |
Arterial RI was a measure of vascular resistance using Doppler ultrasound. RI was the ratio of (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and increased as resistance to blood flow increased. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix.
| ratio | Placebo | Tadalafil |
|---|---|---|
| Change From Baseline to 8-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone | -0.01 ± 0.006 | 0.00 ± 0.006 |
Arterial RI was a measure of vascular resistance using Doppler ultrasound. RI was the ratio of (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and increased as resistance to flow increased. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix.
| ratio | Placebo | Tadalafil |
|---|---|---|
| Change From Baseline to 4-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone | 0.00 ± 0.006 | 0.01 ± 0.006 |
Arterial RI was a measure of vascular resistance using Doppler ultrasound. RI was the ratio of (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and increased as resistance to flow increased. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix.
| ratio | Placebo | Tadalafil |
|---|---|---|
| Week 4 Change, Prostate Peripheral Zone (n=45, 43) | 0.00 ± 0.006 | 0.01 ± 0.007 |
| Week 8 Change, Prostate Peripheral Zone (n=43, 38) | -0.01 ± 0.006 | 0.01 ± 0.007 |
| Week 4 Change, Bladder Neck (n=30, 30) | -0.01 ± 0.012 | 0.01 ± 0.012 |
| Week 8 Change, Bladder Neck (n=32, 26) | 0.01 ± 0.015 | 0.02 ± 0.016 |
CPI quantified blood flow in a pre-specified region of interest by using color Doppler imaging. CPI was the mean color pixel intensity in the region of interest and scores could range from 0 to 160. An increase in CPI reflected an increase in blood flow. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix.
| units on a scale | Placebo | Tadalafil |
|---|---|---|
| Week 4 Change, Prostate Transition Zone (n=44, 43) | -2.21 ± 2.377 | 0.42 ± 2.408 |
| Week 8 Change, Prostate Transition Zone (n=43, 38) | 2.02 ± 1.974 | 2.53 ± 2.083 |
| Week 4 Change, Prostate Peripheral Zone (n=44, 43) | -1.48 ± 2.059 | 1.99 ± 2.091 |
| Week 8 Change, Prostate Peripheral Zone (n=43, 38) | 3.11 ± 1.868 | 2.55 ± 1.987 |
| Week 4 Change, Bladder Neck (n=42, 40) | 7.37 ± 4.022 | 3.17 ± 4.140 |
| Week 8 Change, Bladder Neck (n=38, 36) | -0.13 ± 3.622 | 7.81 ± 3.738 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 2/50 (4%) | 4/50 (8%) |
| Tadalafil | — | 0/47 (0%) | 10/47 (21.3%) |
| Event | Placebo | Tadalafil |
|---|---|---|
| Cardiac arrestCardiac disorders | 1/50 | 0/47 |
| Myocardial infarctionCardiac disorders | 1/50 | 0/47 |
| Carotid artery stenosisNervous system disorders | 1/50 | 0/47 |
| Ischaemic cerebral infarctionNervous system disorders | 1/50 | 0/47 |
| Event | Placebo | Tadalafil |
|---|---|---|
| HeadacheNervous system disorders | 1/50 | 4/47 |
| Abdominal pain upperGastrointestinal disorders | 0/50 | 1/47 |
| DyspepsiaGastrointestinal disorders | 0/50 | 1/47 |
| Gastric disorderGastrointestinal disorders | 0/50 | 1/47 |
| BronchitisInfections and infestations | 0/50 | 1/47 |
| NasopharyngitisInfections and infestations | 0/50 | 1/47 |
| FallInjury, poisoning and procedural complications | 0/50 | 1/47 |
| Rib fractureInjury, poisoning and procedural complications | 0/50 | 1/47 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/50 | 1/47 |
| NephrolithiasisRenal and urinary disorders | 0/50 | 1/47 |
The Primary Analysis Population was defined as all randomized participants who received at least 1 dose of study medication.
| Age Continuous(years) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Mean | 60.3 ± 8.18 | 60.0 ± 7.53 | 60.2 ± 7.83 |
| Sex: Female, Male(Participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 50 | 47 | 97 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 50 | 45 | 95 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 8 | 3 | 11 |
| White | 41 | 42 | 83 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Austria | 6 | 7 | 13 |
| Belgium | 4 | 5 | 9 |
| Italy | 15 | 14 | 29 |
| United States | 25 | 21 | 46 |
| Erectile Dysfunction (ED) Etiology(participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Psychogenic | 0 | 0 | 0 |
| Organic | 18 | 15 | 33 |
| Mixed | 13 | 12 | 25 |
| Unknown | 2 | 2 | 4 |
| ED Severity(participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Mild | 11 | 9 | 20 |
| Moderate | 16 | 15 | 31 |
| Severe | 6 | 5 | 11 |
| ED Duration(participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| <1 year | 4 | 1 | 5 |
| ≥1 year | 28 | 28 | 56 |
7 further baseline measures are reported on the registry.
The record gives a start of Sep 2010, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2013, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil